Pretargeting: General principles; October 10-12, 1996

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2675-2680

  Goodwin, David A ^a,b   Meares, Claude F ^c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biotin avidin; Hapten monoclonal antibody; Radioimmunodetection; Radioimmunotherapy; Yttrium 90

Indexed keywords

ACETIC ACID DERIVATIVE; ANTIBODY CONJUGATE; AVIDIN; BIOTIN; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; HAPTEN; INDIUM; MONOCLONAL ANTIBODY Y 90; PENTETIC ACID; STREPTAVIDIN; TETRAAZACYCLODIDECANETETRAACETIC ACID; UNCLASSIFIED DRUG; YTTRIUM 90;

CONFERENCE PAPER; DRUG DIFFUSION; DRUG TARGETING; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION;

EID: 0031471107     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2675::aid-cncr45>3.0.co;2-6     Document Type: Conference Paper

References (21)

1. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111 labeled bifunctional haptens. J Nucl Med 1988;29:226-68.
2. Axworthy DB, Beaumier PL, Bottino BJ, et al. Preclinical optimization of pretargeted radioimmunotherapy components: high-efficiency, curative Y-90 delivery to mouse tumor xenografts. Tumor Targeting 1996;2(3):156.
3. Reardon DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;16:265-8.
4. Le Doussal J-M, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in-vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 1989;30:1358-66.
5. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 1991;51:6650-5.
6. Schuhmacher J, Klivényi G, Matys R, et al. Multistep tumor targeting in nude mice using bispecific antibodies and a gallium chelate suitable for immunoscintigraphy with positron emission tomography. Cancer Res 1995;55:115-23.
7. Hnatowitch DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med 1987;28:1294-302.
8. Paganelli G, Magnani P, Zito F, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res 1991;51:5960-6.
9. Bagshawe KD. The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Br J Cancer 1989;60:275-81.
10. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J 1990;4:188-93.
11. Bos ES, Kuijpers WHA, Meesters-Winters M, et al. In vitro evaluation of DNA-DNA hybridization as a two-step approach in radioimmunotherapy of cancer. Cancer Res 1994;54:3479-86.
12. Renn O, Goodwin DA, Studer M, Moran JK, Jacques V, Meares CF. New approaches to delivering metal-labeled antibodies to tumors; synthesis and characterization of new biotinyl chelate conjugates for pre-targeted diagnosis and therapy. J Controlled Release 1996;39:239-49.
13. Hu S-z, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) shich exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
14. Pimm MV, Gribben SJ. Prevention of renal tubule re-absorption of radiometal (indium-111) labeled Fab fragment of a monoclonal antibody in mice by systemic administration of lysine. Eur J Nucl Med 1994;21:663-4.
15. Hammond PJ, Wade AF, Gwilliam ME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993;671437-9.
16. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-21.
17. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993;34:2253-63.
18. Goodwin DA, Meares CF, Watanabe N, et al. Pharmacokinetics of pretargeted monoclonal antibody 2D12.5 and Y-88-JANUS-2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclodidecanetetraacetic acid (DOTA) in BALB/c mice with KHJJ mouse adenocarcinoma: a model for Y-90 radioimmunotherapy. Cancer Res 1994;54:5937-46.
19. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-30.
20. van Osdol WW, Sung C, Dedrick RL, Weinstein JN. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J Nucl Med 1993;34:1552-64.
21. Paganelli G, Chinol M, Grana C, Fiorenza M, Cremonesi R, Franseschini R, et al. Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: Bergman H, Kroiss H, Sinzinger H, editors. Radioactive isotopes in clinical medicine and research. 1997:513-7.